By year and billing code | |||||
Year diagnosed | Claim for reporting a molecular testa | ||||
Molecular test 83912 | EGFR | KRAS | Multiple | Totalb | |
2010 | 18,845 | 2,516 | 1,095 | 1,034 | 21,422 |
2011 | 12,254 | 1,235 | 655 | 576 | 13,568 |
2012 | 11,316 | 2,714 | 1,460 | 1,188 | 14,302 |
2013 | – | 12,433 | 4,856 | 3,626 | 13,663 |
Total | 42,415 | 18,898 | 8,066 | 6,424 | 62,955 |
Percent of patients tested | |||||
Years | |||||
2011 | 2012 | 2013 | Change 2011–2013 | ||
Patients diagnosed with lung cancer | 245,576 | 227,929 | 215,036 | −12.4% | |
Patients who a claim for surgical pathology analysisc | 167,291 | 155,408 | 142,469 | −14.8% | |
Patients who had a claim for a molecular testd | 13,008 | 13,818 | 13,259 | 1.9% | |
Percent of patients with tissue who were tested | 7.78 | 8.89 | 9.31 | 19.7% |